Tinker, tailor, soldier, cell: the role of C-type lectins in the defense and promotion of disease

Abstract

C-type lectins (CTLs) represent a large family of soluble and membrane-bound proteins which bind calcium dependently via carbohydrate recognition domains (CRDs) to glycan residues presented on the surface of a variety of pathogens. The deconvolution of a cell’s glycan code by CTLs underpins several important physiological processes in mammals such as pathogen neutralization and opsonization, leukocyte trafficking, and the inflammatory response. However, as our knowledge of CTLs has developed it has become apparent that the role of this innate immune family of proteins can be double-edged, where some pathogens have developed approaches to subvert and exploit CTL interactions to promote infection and sustain the pathological state. Equally, CTL interactions with host glycoproteins can contribute to inflammatory diseases such as arthritis and cancer whereby, in certain contexts, they exacerbate inflammation and drive malignant progression. This review discusses the ‘dual agent’ roles of some of the major mammalian CTLs in both resolving and promoting infection, inflammation and inflammatory disease and highlights opportunities and emerging approaches for their therapeutic modulation.

Graphical abstract

Keywords

C-type lectins / DC-SIGN / MBL / selectins / infection / arthritis / cancer

Introduction

The relationship and interaction between the mammalian host and infectious microorganisms is deep and dynamic, involving hundreds of sensing molecules, signaling cascades and physiological responses. Mammals have evolved alongside infectious pathogens which has shaped their immune system and responses to infection. However, in doing so, pathogens have also developed sophisticated methods to avoid or exploit these defenses to facilitate infection and help circumvent elimination.

“We’ve spent our lives looking for the weaknesses in one another’s systems” Tinker, Tailor, Soldier, Spy by John Le Carré (1974) .

C-type lectins (CTLs) are a superfamily of proteins which contain one or more CTL-domain (CTLD) (Drickamer, 1999; Brown et al., 2018). The CTL family consists of over 1000 proteins split into 17 subgroups and are referred to broadly as “C-type” for the calcium dependency of their glycan interactions (Weis et al., 1992; Cummings and McEver, 2009). However, for some CTLs their CTLD can also bind non-sugar moieties (Cummings and McEver, 2009).

In mammals, CTLs can be both secreted soluble proteins or transmembrane cell surface receptors (Fig. 1) and have calcium-dependent lectin binding specificity for mannose (Man), N-acetylglucosamine (GlcNAc), and fucose (Fuc) (Weis et al., 1992; Mitchell et al., 2001; Arnold et al., 2006a). CTLs play significant roles in immunity including both humoral and cellular compartments and provide an innate first-line defense against pathogens. However, as our understanding of CTLs has developed it has become apparent that their roles extend beyond simply identifying and helping to fight infection. In this review, we consider the double-sided role of CTL interactions in the identification of both pathogen- and host-associated glycoproteins (Malhotra et al., 1995; Arnold et al., 2006a), but also in providing both protection and facilitation of infection and inflammatory disease (Geijtenbeek et al., 2000b; Santos et al., 2001). This review considers how CTLs can act as both “friend” or “foe” in certain biological contexts, focusing on the most well-characterized CTLs including mannose-binding lectin (MBL) (Sim et al., 2016) and CTL receptor (CTLR) dendritic cell-specific ICAM-3-grabbing nonintegrin (CD209; DC-SIGN) (Mitchell et al., 2001) (Fig. 1). A greater understanding of the CTL protein family and their dual-sided “spy networks” could help to identify therapeutic checkpoints, wherein CTL function could be modulated to drive beneficial outcomes.

DC-SIGN in host dynamics and infectious disease

DC-SIGN is a type-2 membrane protein that forms stable tetramers in the plasma membrane (Feinberg et al., 2005). This oligomerization is mediated via α-helical coiled-coil domains and leads to the clustering of four C-type carbohydrate recognition domains (CRDs), in close proximity, to produce a multivalent glycan-binding surface (Fig. 1). Each CRD possesses a Glu-Pro-Asn (EPN) motif that preferentially binds to mannose-type saccharides. DC-SIGN has also been demonstrated to interact with fucosylated oligosaccharides, such as is found on Lewis-x (Le^x; Fig. 2) glycan structures, via an extended binding site that makes multiple contacts with multiple saccharide units within a single oligosaccharide structure (Guo et al., 2004; Feinberg et al., 2007). More recently, further analysis of the binding function of DC-SIGN has demonstrated cues for driving cooperativity in complex ligand interactions, giving rise to higher order interactions that in turn broaden the sensory range of this family of lectins (Wawrzinek et al., 2021). Native DC-SIGN tetramers also have N-terminal transmembrane and intracellular domains, the latter of which carries internalization motifs allowing DC-SIGN to serve as an endocytic receptor on dendritic cells (DCs).

At the turn of the 21^st century, the identification that DC-SIGN could interact with human immunodeficiency virus (HIV) pioneered a new way of approaching lectin-pathogen interactions in human disease. Work by Geijtenbeek et al. uncovered how HIV-1 could bind to DCs in peripheral tissues via the viral carbohydrates that are densely presented on the gp120 glycoprotein of the enveloped virus outer surface (Geijtenbeek et al., 2000b). In this scenario, the principal host binding partner for HIV-1 is DC-SIGN (rather than the well-characterized HIV-gp120 host counterpart, CD4). gp120 has around 40% carbohydrate by mass with 23 N-linked glycosylation sites and DC-SIGN binds to high mannose N-linked oligosaccharides presented on this glycoprotein (Feinberg et al., 2001; Mitchell et al., 2001).

Geijtenbeek et al. went on to outline the role of the DC-SIGN-gp120 interaction in the primary capture of infectious HIV particles in areas such as genital mucosa/lamina propria via DCs that are typically resident there (and where CD4⁺ T cells are typically scarce) (Geijtenbeek et al., 2000b). Subsequently, in keeping with normal DC function, these cells would migrate to regions rich in CD4⁺ T cells, such as lymph nodes, where DC-SIGN-bound HIV-1 particles would then have access to abundant populations of the CD4 co-receptor-positive T cells (especially via the DC-T cell immunological synapse) within which the virus can efficiently proliferate (Cameron et al., 1992). This phenomenon has been termed as infection in trans and generated new hypotheses around how a persistent pathogen within the host, such as HIV-1, can achieve efficient primary infection of CD4⁺ T cells and potentially be sequestered and trafficked within the body to evade neutralization and prolong survival. The utilization of DC-SIGN in such an orthogonal set of virus–host interactions has been investigated in other infectious diseases, leading to a broadening of perspectives as to how pathogens can subvert host immune responses via pathogen carbohydrate binding by host lectins, especially CTLs. A range of both lectins and pathogens has been demonstrated to contribute to these systems of orthogonal interactions. Pathogens include Mycobacterium tuberculosis (Geijtenbeek et al., 2003), and Helicobacter pylori (Bergman et al., 2004) and viruses such as influenza A (Hillaire et al., 2013; Yang et al., 2021), Ebola (Simmons et al., 2003), and the severe acute respiratory syndrome coronavirus (SARS-CoV, including SARS-CoV-2) (Chan et al., 2006; Amraei et al., 2021; Cai et al., 2021). In addition, DC-SIGN also binds to the DENV glycoprotein of Dengue virus, promoting virus interactions with human DCs (Navarro-Sanchez et al., 2003; Liu et al., 2017). CTLs of particular interest in relation to infection in trans include DC-SIGN and also DC-SIGN-related protein (DC-SIGNR also known as L-SIGN; CD299) and surfactant protein-A and -D (SP-A and -D; Fig. 1) which will be discussed further below.

DC-SIGN has been demonstrated to be exploited by HIV-1 for survival in the host. HIV-1 contact with DC sequesters and stabilizes viral particles in cycling endosomes during the journey to T cell-rich areas (Kwon et al., 2002). Furthermore, the intracellular signaling properties of DC-SIGN invoked by virus contact influence the immunobiological function of the DCs. Gringhuis and colleagues demonstrated that signaling via DC-SIGN stimulates Raf-1 kinase-associated systems that modulate Toll-like receptor (TLR) responses in cells that co-express these receptors (Gringhuis et al., 2007; Gringhuis et al., 2009). The outcome of this modulation of TLR signaling leads to NF-kappa-B p65 acetylation and polarizes the cell towards anti-inflammatory/immunosuppressive responses, such as promoting IL-10 secretion and suppressing IL-12 production. Consequently, the scale-up of this immunosuppressive polarization broadly downregulates responses that would normally combat viruses such as HIV-1. Therefore, this subversion of immune function via engagement with DC-SIGN favors the survival of an exogenous threat (HIV-1). These remarkable insights relating to DC-SIGN led researchers to investigate other major pathogens and especially highlighted M. tuberculosis as a microbial species that can interact with DC-SIGN (Geijtenbeek et al., 2003). Mycobacterial binding has been demonstrated to occur via their carbohydrate-rich mannosylated lipoarabinomannan (ManLAM) surfaces, supporting internalization into target cells and also immunosuppression with overlapping mechanisms utilized by HIV-1. Furthermore, additional glycoprotein ligands for DC-SIGN have been identified from M. bovis bacillus Calmette-Guérin (BCG) extracts (Carroll et al., 2010), in particular the lipoarabinomannan carrier protein lprG which can also engage TLR2, and thus suggests that certain pathogens can possess networks of molecules that help to reprogram or polarize the host responses towards an immunosuppressed state that is a hallmark of tuberculosis (van Kooyk et al., 2003).

Beyond DC-SIGN, other CTLs have been implicated in promoting infection and/or pathogen survival within the host, including further exploitation of these lectins by HIV-1. It has been demonstrated that the soluble collectin molecules SP-A and SP-D (Fig. 1) can also interact with the heavily glycosylated HIV particles through their CRDs (which are broadly homologous to the CRD of DC-SIGN). In addition to their presence in pulmonary surfactant, SP-A and SP-D are also present in genital mucosae where HIV-1 can make primary contact with the host. Studies by Gaiha et al. and Madsen et al. have demonstrated that SP-A and SP-D display a dual modulatory role in HIV-1 infection, whereby viral particles can be targets for binding but these opsonized viral particles then become engulfed by DCs and trafficked to the lymph nodes which (as described above) promotes infection (Gaiha et al., 2008; Madsen et al., 2013). DC-SIGNR has also been implicated in HIV-1 infection in trans, although its distribution is significantly different from DC-SIGN, being expressed principally in lymph node and hepatic endothelium rather than DCs and selected subpopulations of macrophage (Soilleux et al., 2000; Pohlmann et al., 2001; Soilleux et al., 2002).

As with many immune receptors and interactions, the response can be context dependent, and despite the unraveling of the important roles for DC-SIGN in infectious disease, this has also uncovered a role for the receptor in immune tolerance. Before receiving its moniker as DC-SIGN in 2000, the molecule was previously identified in the placenta (Curtis et al., 1992), and was later found to be heavily expressed on both placental Hofbauer cells and maternal decidual macrophages (Soilleux et al., 2001). This concentration of DC-SIGN at the feto-maternal interface strongly suggests that it is involved in the immunological tolerance that arises during pregnancy and indeed primate models show that DC-SIGN expression in uterine decidua heralds the onset of pregnancy (Breburda et al., 2006). In human pregnancy, downregulation of DC-SIGN on placental Hofbauer cells has been demonstrated to correlate with complications such as pre-eclampsia (Yang et al., 2017). Beyond tolerance in pregnancy, DC-SIGN may also be involved in establishing and maintaining accommodation of allografts, with considerable potential in understanding transplantation immunology (Conde et al., 2015). With further involvement of DC-SIGN in apoptotic cell uptake, consolidation of the immunological synapse via ICAM-3 binding (Geijtenbeek et al., 2000c), support of DC vascular trafficking via ICAM-2 binding (Geijtenbeek et al., 2000a), and engagement of neutrophils by DCs (van Gisbergen et al., 2005), it is evident that the natural function of DC-SIGN in particular lies in moderating the tolerogenic axis of host immunity and inflammation. It is therefore unsurprising that certain pathogens have evolved ligands and mechanisms to exploit such networks to evade eradication by host defenses.

MBL and the detection of self and non-self glycans

MBL is a member of the collectin family which is synthesized in the liver and circulates in the blood stream. Serum concentrations of MBL in the blood vary greatly between individuals with a mean of 2.4 ± 2.7 µg/mL and is undetectable in the serum of up to 20% of individuals (Mayilyan et al., 2006). This variation is a result of polymorphisms in the coding sequence and/or the promoter regions of the gene for MBL (Madsen et al., 1998). Polymorphisms within the coding region often interfere with the oligomerization of the MBL subunits at the protein level which compromises their avidity of binding sugar-ligands (Larsen et al., 2004). MBL is structurally similar to that of the complement protein C1q (Reid, 2018), composed of monomers of 25 kDa (each with its own CRD) which trimerize via a collagen triple helix, and 2–6 of these timers then oligomerize to form the higher-order structures of MBL that resemble a “bunch of tulips” arrangement (Fig. 1) (Arnold et al., 2005a; Auriti et al. 2017). Although the affinity of a single CRD to a sugar is weak (Iobst and Drickamer, 1994), MBL’s higher-order oligomers facilitate greater overall avidity of binding through permitting engagement of multiple CRDs (Kjaer et al., 2013).

MBL is one of the key activators of the lectin pathway of complement activation through its MBL-associated serine proteases (MASP-1–3) (Presanis et al., 2004; Tsakanova et al., 2018) (Fig. 3). MASP-2 has been demonstrated to be the crucial MASP and is sufficient to activate the complement cascade alone (Thiel et al., 1997; Merle et al., 2015). Upon MBL binding via its CRDs, MASP-2 autoactivates and cleaves complement factor C4 to generate C4a and C4b fragments, which exposes a thioester group which allows C4b to covalently bind to the activating surface (Ambrus et al., 2003; Moller-Kristensen et al., 2007; Schwaeble et al., 2011) (Fig. 3). Subsequently, complement factor C2 then binds C4b to be cleaved by MASP-2 to generate C2a which remains bound to C4b and becomes the C3 convertase (C4b2a). The C3 convertase subsequently cleaves complement component C3 to generate C3b, which covalently binds to proximal surfaces via a thioester group and is subsequently cleaved to form iC3b that can act as a potent opsonin (Fig. 3). Additionally, activation of C3 leads to the formation of the membrane attack complex (MAC) that causes cell lysis (Fig. 3). There is evidence that MASP-2 can directly cleave C3 at a low level (Ambrus et al., 2003) which could explain the residual lectin pathway activity reported in the absence of C4 and/or C2 components (Yaseen et al., 2017). However, unlike MASP-2, the role of MASP-1 and -3 is not as clearly defined. There is evidence that MASP-1 may play a role in activating MASP-2 (Heja et al., 2012) and augmenting MASP-2 activity through directly cleaving C2 (Chen and Wallis, 2004), however, as MASP-1 cannot cleave C4 it is insufficient to fully activate complement on its own. Interestingly, Sim, R.B. and colleagues demonstrated that MASP-1 was capable of cleaving factor XIII and fibrinogen (Krarup et al., 2008) suggesting an alternative role for the enzyme potentially associated with coagulation (Presanis et al., 2004; Krarup et al., 2007). In addition to MASP-1–3, there are also two non-enzymatic MASP splice variants; MAp44 (Degn et al., 2009) and MAp19 (Stover et al., 1999; Iwaki et al., 2006; Degn et al., 2011). Although the role of these splice variants remain debated, there is evidence that they may play a regulatory role for MASP activation (Iwaki et al., 2006; Degn et al., 2009; Degn et al., 2013).

In addition to complement activation, MBL binding can have a direct neutralizing/opsonising role of pathogenic material, where it has been demonstrated to bind to glycans presented on a range of pathogens including; bacteria (Neth et al., 2000), virus (Kase et al., 1999; Ji et al., 2005; Brown et al., 2010; Murugaiah et al., 2021), yeast (Lillegard et al., 2006; Brouwer et al., 2008), and parasites (Green et al., 1994). MBL-bound pathogens are then phagocytosed by macrophages/DCs through MBL receptors to promote clearance (Malhotra et al., 1990; Ogden et al., 2001; Presanis et al., 2003). MBL binding can also have a neutralization effect and can prevent viral entry into cells (Kase et al., 1999; Ji et al., 2005; Brown et al., 2010). The importance of MBL’s interactions with pathogens has been most clearly observed and defined in infants, where low levels of serum MBL have been linked to severe and recurrent infection (Summerfield et al., 1997; Faber et al., 2007) and greater risk of developing neonatal sepsis (Gao et al., 2015). In adults, low levels of circulating MBL have been associated with recalcitrant rhinosinusitis (Justice et al., 2015) and increased mortality from pneumococcal infection (Eisen et al., 2008). However, other studies have failed to find such links to suseptability to meningococcal disease (Bradley et al., 2012). Despite these important roles for MBL in controlling infection, these pathways have also been exploited by some pathogens to improve infection. In another example of “friend” turns “foe”, it has been demonstrated that intracellular pathogens like Leishmania, exploit the opsonizing capabilities of MBL to actively facilitate their entry into cells (Santos et al., 2001). Interestingly, MBL can also play an immune-modulating role when bound to pathogenic material. For example, MBL-opsonized material has been shown to influence the functionality of monocyte/macrophages to TLR ligands, reducing their expression of pro-inflammatory cytokines such as IL-1α and IL-1β and increasing their expression of the anti-inflammatory cytokine IL-10 upon lipopolysaccharide (LPS) stimulation (Fraser et al., 2006). This effect is not just restricted to myeloid cells but also lymphocytes where T cell engagement with MBL’s collagen-like domains by calreticulin on the T cell surface reduces proliferation and T cell receptor signaling (Zhao et al., 2017). These modulating roles of MBL, which skew a more anti-inflammatory state of the host immune response, potentially act as a mechanism to facilitate the resolution phase of the immune reaction. MBL’s role in modulating the immune response could also help to explain the link between low serum MBL levels and auto-immune disease (Garred et al., 2000; Tsutsumi et al., 2005).

Up to the mid-1990s the role of MBL was exclusively associated with detecting and clearing pathogens, however, a seminal article from Sim, R.B. and colleagues changed this perception of CTLs when they demonstrated that MBL could bind to a glycoform of the host protein immunoglobulin G (IgG) and activate complement (Malhotra et al., 1995). IgG has a single conserved N-linked glycosylation site at asparagine (Asn)-297 on each of its heavy chains which are situated in the Fc portion of the molecule (Fig. 4). The glycans which occupy this site are generally highly processed to terminal galactose and sialic acids (Arnold et al., 2005a), however in the serum from healthy individuals about 25% of IgG glycans are missing these sugars and display terminal GlcNAc residues, referred to as “IgG-G0” glycoforms (for their lack of terminal galactose; Fig. 4) (Parekh et al., 1985; Arnold et al., 2007). Interestingly, in chronic inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis, the prevalence of IgG-G0 significantly increases to >50% of the IgG pool (Parekh et al., 1985). Subsequent studies identified increased IgG-G0 in a range of inflammatory conditions including Crohn’s disease, juvenile onset chronic arthritis, systemic lupus erythematosus complicated by Sjögren’s syndrome and tuberculosis (Parekh et al., 1985; Parekh et al., 1989; Bond et al., 1997). Serum elevations of IgG-G0 in chronic inflammatory conditions appear to be directly linked to the underlying inflammatory state, as IgG-G0 levels in patients with RA return to baseline levels during pregnancy when there is a remission of the disease (Rook et al., 1991). Other CTLs and CTLRs have been demonstrated to interact with IgG-G0 glycans such as macrophage mannose receptor (MMR) (Dong et al., 1999) (Fig. 1). Although Fc receptor-mediated interactions have been demonstrated to play a major role in IgG-G0 cellular effects (Nimmerjahn et al., 2007), the observation by Sim et al., (Malhotra et al., 1995) provided added functionality to MBL and identified that the crosstalk between the complement system and IgG was not just through C1q and the classical pathway of complement activation, but also extended to the lectin pathway (Fig. 3).

MBL’s interaction with host glycoproteins is not just restricted to IgG. MBL has also been demonstrated to bind glycoforms of human IgM which are enriched for their presentation of terminal GlcNAc residues (Arnold et al., 2005b) and dimeric/polymeric forms of IgA (Roos et al., 2001; Royle et al., 2003). Furthermore, MBL interacts with oligomannose glycans present on the serum thioester protein α2-macroglobulin (Arnold et al., 2006b). MBL has also been demonstrated to interact with populations of host cells including B-cells (Downing et al., 2005), DCs (Downing et al., 2003; Downing et al., 2005), senescent fibroblasts (Tomaiuolo et al., 2012) and apoptotic cells (Ogden et al., 2001) through its CRDs in a sugar-dependent manner. Clearance of apoptotic cells has emerged as a significant function of MBL which has been demonstrated elegantly in vitro and in vivo (Stuart et al., 2005). These studies highlight the diverse roles of MBL, and CTL interactions more generally, which can play pivotal roles in both pathogen identification but also provide a mechanism of cross-communication between host proteins associated with the immune response.

Selectins and cell trafficking

Selectins are a type I membrane class of CTLR which bind sialoglycans. There are three members of the family; L-, E-, and P-selectin, named after their expression on leukocytes, endothelium, and platelets, respectively (Fig. 1). However, their expression is not as selective as their name infers where, for example, endothelial cells express both E- and P-selectin (McEver, 2015). Selectins have specificity for sialyl Lewis-x (SLe^x) and its isomer glycan, sialyl Lewis-a (SLe^a) (Fig. 2). The minimal glycan epitope for SLe^x is a sialic acid residue α2,3-linked to galactose with a fucose α1,3-linked to GlcNAc. The interaction between SLe^x/a epitopes and E- and P-selectin expressed by endothelial cells has emerged as a crucial interaction in facilitating leukocyte recruitment to inflammatory sites, which has been extensively reviewed (McEver, 2015). Although there are sites where E-selectin is constitutively expressed, such as the bone marrow (Schweitzer et al., 1996), it is not present on most endothelial cell surfaces during homeostatic conditions, but is highly inducible in the presence of inflammatory stimulants such as tumor necrosis factor-alpha (TNF), IL-1β and LPS (Wong and Dorovini-Zis, 1996). Leukocyte engagement with selectins expressed on endothelial cells via SLe^x/a epitopes presented on their surface provides the initial anchoring interaction which permits slowing and rolling of leukocytes along the endothelium (Kunkel and Ley, 1996) (Fig. 5). Once slowed against the sheer force of the blood stream, leukocytes become activated by chemokines and other chemoattractants that are diffusing from the inflammatory site (or expressed by the activated endothelium) which results in the activation and engagement of β2-integrin interactions on the leukocyte surface (Alon and Feigelson, 2012; Lefort and Ley, 2012) (Fig. 5). In the resting state, β2-integrins adopt a “clasped” inactivated heterodimer form, but once activated, a structural change permits more efficient integrin interactions (Alon and Feigelson, 2012; Lefort and Ley, 2012) (Fig. 5). Leukocyte β2-integrins permits a firmer adhesion through engagement with intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) which are expressed on activated endothelium and results in migration arrest and crawling of the leukocyte with eventual transmigration through the endothelial layer into the site of inflammation (Fig. 5). CTL interactions are fundamental to leukocyte recruitment to inflammatory microenvironments. However, such interactions in chronic inflammatory conditions can exacerbate disease pathogenesis, such as is observed in arthritis (Hopkin et al., 2019) and cancer (Natoni et al., 2016). The implications of selectins in cancer will be discussed in the next section.

CTLs and tumor progression

Changes in glycosylation patterns in cancer are common and can be associated with genetic alterations (Radcliffe et al., 2007) or cancer-associated inflammation which modifies cellular glycosylation processing machinery (Arnold et al., 2008; Pinho and Reis, 2015). Two if the most well-characterized N-linked glycosylation changes in cancer are associated with the degree of branching, dictated by the number of GlcNAcs attached to the chitobiose core and the prevalence of SLe^x (Saldova et al., 2007; Arnold et al., 2011) (Fig. 2). As described in the previous section, selectins bind SLe^x glycan epitopes on leukocytes to promote their recruitment from the blood, which can be exploited in cancer to recruit pro-tumoral cell types such as macrophages into the tumor which facilitate disease progression (Muliaditan et al., 2018; Opzoomer et al., 2021) and metastasis (Laubli and Borsig, 2010; Natoni et al., 2016; Esposito et al., 2019). SLe^a epitopes (Fig. 2) on the surface of tumor cells promote their rolling and extravasation from the blood stream (Ben-David et al., 2008; Heidemann et al., 2014) and facilitate metastatic niche formation (Laubli et al., 2009). In acute myeloid leukemia (AML), E-selectin helps to retain tumor stem cells within a bone marrow vascular niche which protects these cells from the effect of cytotoxic chemotherapeutics (Barbier et al., 2020).

Follicular lymphoma (FL) is a B cell malignancy that represents about 40% of all non-Hodgkin lymphomas. A seminal article by Stevenson et al. demonstrated that aberrant N-linked glycosylation sites in the B cell receptor (BCR) Fab region of the surface immunoglobulin (Ig) were common, almost a characteristic feature, in FL (Radcliffe et al., 2007). These N-linked glycosylation sites were introduced though opportunistic selection during somatic hypermutation in the Ig Fab variable region of the BCR. Despite the apparent accessibility of the N-linked glycans for processing to higher order sugars, the glycans attached to the Fab in FL remained relatively unprocessed high oligomannose glycans which were targets for CTL engagement (Radcliffe et al., 2007). Since this seminal article, aberrant high oligomannose glycans on the surface Ig in FL have been demonstrated to interact with CTLRs such as DC-SIGN (Coelho et al., 2010; Amin et al., 2015; Linley et al., 2015; Valle-Argos et al., 2021) and MMR (Coelho et al., 2010) (Fig. 1) which provide an antigen-independent activating signal to the B cells. Macrophages which reside in the tumor, referred to as tumor associated macrophages (TAMs), are a highly plastic stromal cell type which facilitate cancer progression (DeNardo et al., 2009; Murray et al., 2014; Mantovani et al., 2017; Muliaditan et al., 2018; Opzoomer et al., 2021) and express DC-SIGN (Amin et al., 2015) and MMR within the tumor microenvironment. More recently, it has been demonstrated that CTLR engagement with the surface Ig Fab glycans in FL acts to block higher-affinity antigen engagement as a mechanism to protect the B cells from over-stimulation while concurrently providing a persistent low-level activation signal to these cells (Valle-Argos et al., 2021), providing a driver mechanism for cancer progression that is driven by CTL binding.

Tumor cells can present aberrant glycosylation which permit binding of CTLs, such as MBL (Terada et al., 2005). DC-SIGN binds Mac-2-binding proteins (Mac-2BP) expressed by a variety of colorectal cancer cell lines through their α1-3/4-fucose moieties of Le glycans, where engagement attenuates DC maturation (Nonaka et al., 2011). DC-SIGN can also engage with Le glycans on carcinoembryonic antigen (CEA) and CEA-related adhesion molecule-1 (CEACAM1) (Nonaka et al., 2008). In vitro studies have demonstrated that this interaction also modulates DC maturation and skews their cytokine profiles to a more immune-modulatory phenotype, secreting higher levels of IL-6 and IL-10 (Nonaka et al., 2008). As such, the engagement of DC-SIGN to aberrant cancer glycans has the potential to contribute towards suppressing the anti-tumor immune response. This is supported by the observation that conditioned media from tumor cell: DCs co-cultures was able to suppress Th1 responses in vitro (Nonaka et al., 2008). Another CTL, Mincle (Clec4e) has also been associated with suppression of T cell mediated tumor control (Seifert et al., 2016). Mincle signaling on TAMs in murine LL2 and B16 tumors has been demonstrated to promote macrophage polarization to a pro-tumoral phenotype which facilitates progression of the disease (Li et al., 2020). The Tn glycan epitope presented on tumor-associated glycoproteins has also been demonstrated to be a target for macrophage galactose-type lectin receptor (MGL, CD301) which can discriminate between healthy and tumor-associated glycans of the mucin MUC1 (Saeland et al., 2007). MGL engagement with the Tn glycans presented on CD45 of activated T cells has also been demonstrated to compromise T cell proliferation and activity (van Vliet et al., 2006). However, not all CTLR engagement in cancer results in a pro-tumoral function. For example, Dectin-1 expressed on macrophages and DCs has conversely been demonstrated to play an immune-licencing role for natural killer (NK) cell activation to facilitate an anti-tumor immune response (Chiba et al., 2014). Dectin-1 signals through an interferon regulatory factor-5 (IRF5)-dependent pathway (del Fresno et al., 2013), which provides a pro-inflammatory activating signal for DCs. Dectin-1 engagement with aberrant N-linked glycosylation presented on murine B16 melanoma cells improved DC’s licencing of NK cell killing function which prevented tumor formation (del Fresno et al., 2013). As such, in chronic inflammatory conditions CTL and CTLR interactions can exacerbate the underling disease pathology and be exploited by cancer to facilitate disease progression, where such axes have started to be explored as therapeutic targets.

Therapeutic opportunities and conclusions

Following the emergence of CTLs onto the scientific stage around forty years ago (Ashwell and Harford, 1982), the understanding of their function and value has grown from initial impressions of glycoprotein clearance and microbial recognition to broad and deep participation in mammalian homeostasis, immunity and host-pathogen relationships, inflammation control, and tumor survival mechanisms (Fig. 6). This increase in valuable knowledge has been accompanied by the rapid expansion of glycomics as a major scientific discipline in the 21^st century (Guile et al., 1996; Mrksich, 2004). Significantly, the impact of greater knowledge of CTLs has recently led to promising new therapeutic opportunities.

As described in this review, CTLs play an important role in both the detection of pathogen- and host-associated glycans and these axes have considerable opportunity for therapeutic intervention and modulation (Fig. 6). CTLs can be used as recombinant therapeutic preparations or be targets of carbohydrate-conjugated pharmacological agents. E-selectin contributes to chemotherapy resistance in AML has been targeted therapeutically in patients using the glyco-mimetic drug, GMI-1271, which improves responses to chemotherapy (Garcia-Manero et al., 2017) and is currently in a Phase III trial for relapsed and refractory AML (NCT03616470). Chimeric antigen receptor (CAR) T cell immunotherapy, which involves the genetic modification of a patient’s T cells to express activatory CARs with specificity for tumor associated antigens for eventual reinfusion back into a patient (Kosti et al., 2018), have been glyco-engineered to present increased SLe^x epitopes to facilitate their accumulation in the solid tumor microenvironment (Mondal et al., 2019). There are many therapeutic antibodies used in the treatment of cancer (Zahavi and Weiner, 2020) and, interestingly, IgG-G0 is often their predominant glycoform (Mimura et al., 2018). In light of the IgG-G0 glycan interaction with CTLs such as MBL which have the potential to activate complement (Malhotra et al., 1995), it is interesting to consider the potential role of CTLs in the therapeutic response to these antibodies where glyco-engineering approaches can be employed to generate the optimal glycan profiles (Mimura et al., 2018). There has also been considerable interest in utilizing recombinant human SP-D for the treatment of lung diseases, especially in children, to bind pathogens and allergens in the lung via its CRDs, to neutralize the material whilst engaging with immune cells to enhance their anti-inflammatory effects (Strong et al., 2003; Clark, 2010; Arroyo and Kingma, 2021). Within the field of short interfering RNA (siRNA) therapeutics, significant progress has also been made by conjugating specific siRNA oligonucleotides with N-acetylgalactosamine (GalNAc) sugars to engage the asialoglycoprotein receptor (ASGPR; also known as the Ashwell receptor), which is a CTL expressed almost exclusively on hepatocytes of the liver. The ASGPR has unique and very high selectivity for GalNAc and is highly endocytic upon engagement, making it an ideal molecule to target in order to promote exclusive uptake and internalization of siRNA molecules within the liver to correct metabolic disorders (Nair et al., 2014). Recently, the first licensed GalNAc-conjugated siRNA drug, Inclisiran, has been approved for the treatment of dyslipidemia (an abnormal level of lipids in the blood) via knockdown of the PSCK9 gene in hepatocytes to lower systemic low-density lipoproteins (Lamb, 2021; Santulli et al., 2021). This is expected to be the first of many GalNAc-siRNA therapeutics that will rely on the specificity and function of ASPGR to deliver therapeutics to the liver.

In summary, as discussed here, CTLs and CTLRs play a diverse range of functions which can both promote the clearance of infection and resolution of inflammation but in certain contexts be exploited to aid infection by pathogens and exacerbate inflammatory disease. As our understanding of these axes has become deeper, the knowledge for how and where to therapeutically target these interactions most effectively is equally becoming clearer.

References

[1] Alon R, Feigelson SW. Chemokine-triggered leukocyte arrest: force-regulated bi-directional integrin activation in quantal adhesive contacts. Curr Opin Cell Biol 2012;24:670–676.

[2] Ambrus G, Gal P, Kojima M, et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol 2003;170:1374–1382.

[3] Amin R, Mourcin F, Uhel F, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood 2015;126:1911–1920.

[4] Amraei R, Yin W, Napoleon MA, et al. CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2. ACS Cent Sci 2021;7:1156–1165.

[5] Arnold JN, Dwek RA, Rudd PM, et al. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 2006a;106:103–110.

[6] Arnold JN, Royle L, Dwek RA, et al. Human immunoglobulin glycosylation and the lectin pathway of complement activation. Adv Exp Med Biol 2005a;564:27–43.

[7] Arnold JN, Saldova R, Galligan MC, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011;10:1755–1764.

[8] Arnold JN, Saldova R, Hamid UM, et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008;8:3284–3293.

[9] Arnold JN, Wallis R, Willis AC, et al. Interaction of mannan binding lectin with alpha2 macroglobulin via exposed oligomannose glycans: a conserved feature of the thiol ester protein family? J Biol Chem 2006b;281:6955–6963.

[10] Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007;25:21–50.

[11] Arnold JN, Wormald MR, Suter DM, et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem 2005b;280:29080–29087.

[12] Arroyo R, Kingma PS. Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem. Respir Res 2021;22:141.

[13] Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531–554.

[14] Auriti C, Prencipe G, Moriondo M, et al. Mannose-binding lectin: biologic characteristics and role in the susceptibility to infections and ischemia-reperfusion related injury in critically ill neonates. J Immunol Res 2017;2017:7045630.

[15] Barbier V, Erbani J, Fiveash C, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat Commun 2020;11:2042.

[16] Ben-David T, Sagi-Assif O, Meshel T, et al. The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. Immunol Lett 2008;116:218–224.

[17] Bergman MP, Engering A, Smits HH, et al. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J Exp Med 2004;200:979–990.

[18] Bond A, Alavi A, Axford JS, et al. A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. J Autoimmun 1997;10:77–85.

[19] Bradley DT, Bourke TW, Fairley DJ, et al. Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case-control study and a systematic review. Int J Immunogenet 2012;39:328–337.

[20] Breburda EE, Dambaeva SV, Slukvin II, et al. Selective distribution and pregnancy-specific expression of DC-SIGN at the maternal-fetal interface in the rhesus macaque: DC-SIGN is a putative marker of the recognition of pregnancy. Placenta 2006;27:11–21.

[21] Brouwer N, Dolman KM, van Houdt M, et al. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008;180:4124–4132.

[22] Brown GD, Willment JA, Whitehead L. C-type lectins in immunity and homeostasis. Nat Rev Immunol 2018;18:374–389.

[23] Brown KS, Keogh MJ, Owsianka AM, et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010;1:664–674.

[24] Cai G, Du M, Bosse Y, et al. SARS-CoV-2 impairs dendritic cells and regulates DC-SIGN gene expression in tissues. Int J Mol Sci 2021;22:9228–9248.

[25] Cameron PU, Freudenthal PS, Barker JM, et al. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992;257:383–387.

[26] Carroll MV, Sim RB, Bigi F, et al. Identification of four novel DC-SIGN ligands on Mycobacterium bovis BCG. Protein Cell 2010;1:859–870.

[27] Chan VS, Chan KY, Chen Y, et al. Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat Genet 2006;38:38–46.

[28] Chen CB, and Wallis R. Two mechanisms for mannose-binding protein modulation of the activity of its associated serine proteases. J Biol Chem 2004;279:26058–26065.

[29] Chiba S, Ikushima H, Ueki H, et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. Elife 2014;3:e04177.

[30] Clark HW. Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease? Neonatology 2010;97:380–387.

[31] Coelho V, Krysov S, Ghaemmaghami AM, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci USA 2010;107:18587–18592.

[32] Conde P, Rodriguez M, van der Touw W, et al. DC-SIGN(+) macrophages control the induction of transplantation tolerance. Immunity 2015;42:1143–1158.

[33] Cummings RD, McEver RP. C-type Lectins. In Essentials of Glycobiology, nd, Varki A., Cummings R.D., Esko J.D., Freeze H.H., Stanley P., Bertozzi C.R., Hart G.W., and Etzler M.E., eds. NY: Cold Spring Harbor, 2009.

[34] Curtis BM, Scharnowske S, Watson AJ. Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci USA 1992;89:8356–8360.

[35] Damerell D, Ceroni A, Maass K, et al. The GlycanBuilder and GlycoWorkbench glycoinformatics tools: updates and new developments. Biol Chem 2012;393:1357–1362.

[36] Degn SE, Hansen AG, Steffensen R, et al. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol 2009;183:7371–7378.

[37] Degn SE, Jensen L, Olszowski T, et al. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J Immunol 2013;191:1334–1345.

[38] Degn SE, Thiel S, Nielsen O, et al. MAp19, the alternative splice product of the MASP2 gene. J Immunol Methods 2011;373:89–101.

[39] DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91–102.

[40] Dodds AW, Ren XD, Willis AC, et al. The reaction mechanism of the internal thioester in the human complement component C4. Nature 1996;379:177–179.

[41] Dong X, Storkus WJ, Salter RD. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol 1999;163:5427–5434.

[42] Downing I, Koch C, Kilpatrick DC. Immature dendritic cells possess a sugar-sensitive receptor for human mannan-binding lectin. Immunology 2003;109:360–364.

[43] Downing I, MacDonald SL, Turner ML, et al. Detection of an autologous ligand for mannan-binding lectin on human B lymphocytes. Scand J Immunol 2005;62:507–514.

[44] Drickamer K. C-type lectin-like domains. Curr Opin Struct Biol 1999;9:585–590.

[45] Eisen DP, Dean MM, Boermeester MA, et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 2008;47:510–516.

[46] Esposito M, Mondal N, Greco TM, et al. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat Cell Biol 2019;21:627–639.

[47] Faber J, Schuessler T, Finn A, et al. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr Infect Dis J 2007;26:243–246.

[48] Feinberg H, Castelli R, Drickamer K, et al. Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J Biol Chem 2007;282:4202–4209.

[49] Feinberg H, Guo Y, Mitchell DA, et al. Extended neck regions stabilize tetramers of the receptors DC-SIGN and DC-SIGNR. J Biol Chem 2005;280:1327–1335.

[50] Feinberg H, Mitchell DA, Drickamer K, et al. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001;294:2163–2166.

[51] Fraser DA, Bohlson SS, Jasinskiene N, et al. C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol 2006;80:107–116.

[52] del Fresno C, Soulat D, Roth S, et al. Interferon-beta production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity 2013;38:1176–1186.

[53] Gaiha GD, Dong T, Palaniyar N, et al. Surfactant protein A binds to HIV and inhibits direct infection of CD4+ cells, but enhances dendritic cell-mediated viral transfer. J Immunol 2008;181:601–609.

[54] Gao DN, Zhang Y, Ren YB, et al. Relationship of serum mannose-binding lectin levels with the development of sepsis: a meta-analysis. Inflammation 2015;38:338–347.

[55] Garcia-Manero G, Sekeres MA, Egyed M, et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts. Leukemia 2017;31:2799–2806.

[56] Garred P, Madsen HO, Marquart H, et al. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol 2000;27:26–34.

[57] Geijtenbeek TB, Krooshoop DJ, Bleijs DA, et al. DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 2000a;1:353–357.

[58] Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000b;100:587–597.

[59] Geijtenbeek TB, Torensma R, van Vliet SJ, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000c;100:575–585.

[60] Geijtenbeek TB, Van Vliet SJ, Koppel EA, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003;197:7–17.

[61] van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, et al. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 2005;201:1281–1292.

[62] Green PJ, Feizi T, Stoll MS, et al. Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Mol Biochem Parasitol 1994;66:319–328.

[63] Gringhuis SI, den Dunnen J, Litjens M, et al. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007;26:605–616.

[64] Gringhuis SI, den Dunnen J, Litjens M, et al. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009;10:1081–1088.

[65] Guile GR, Rudd PM, Wing DR, et al. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 1996;240:210–226.

[66] Guo Y, Feinberg H, Conroy E, et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol 2004;11:591–598.

[67] Heidemann F, Schildt A, Schmid K, et al. Selectins mediate small cell lung cancer systemic metastasis. PLoS One 2014;9:e92327.

[68] Heja D, Kocsis A, Dobo J, et al. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci U S A 2012;109:10498–10503.

[69] Hillaire ML, Nieuwkoop NJ, Boon AC, et al. Binding of DC-SIGN to the hemagglutinin of influenza A viruses supports virus replication in DC-SIGN expressing cells. PLoS One 2013:8;e56164.

[70] Hopkin SJ, Lewis JW, Krautter F, et al. Triggering the resolution of immune mediated inflammatory diseases: can targeting leukocyte migration be the answer? Front Pharmacol 2019;10:184.

[71] Iobst ST, Drickamer K. Binding of sugar ligands to Ca(2+)-dependent animal lectins. II. Generation of high-affinity galactose binding by site-directed mutagenesis. J Biol Chem 1994;269:15512–15519.

[72] Iwaki D, Kanno K, Takahashi M, et al. Small mannose-binding lectin-associated protein plays a regulatory role in the lectin complement pathway. J Immunol 2006;177:8626–8632.

[73] Ji X, Olinger GG, Aris S, et al. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 2005;86:2535–2542.

[74] Justice JM, Sleasman JW, Lanza DC. Recalcitrant rhinosinusitis, innate immunity, and mannose-binding lectin. Ann Otol Rhinol Laryngol 2015;124:102–106.

[75] Kase T, Suzuki Y, Kawai T, et al. Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology 1999;97:385–392.

[76] Kjaer TR, Thiel S, Andersen GR. Toward a structure-based comprehension of the lectin pathway of complement. Mol Immunol 2013;56:222–231.

[77] van Kooyk Y, Appelmelk B, Geijtenbeek TB. A fatal attraction: Mycobacterium tuberculosis and HIV-1 target DC-SIGN to escape immune surveillance. Trends Mol Med 2003;9:153–159.

[78] Kosti P, Maher J, Arnold JN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol 2018;9:1104.

[79] Krarup A, Gulla KC, Gal P, et al. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 2008;1784:1294–1300.

[80] Krarup A, Wallis R, Presanis JS, et al. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2007;2:e623.

[81] Kunkel EJ, Ley K. Distinct phenotype of E-selectin-deficient mice. E-selectin is required for slow leukocyte rolling in vivo. Circ Res 1996;79:1196–1204.

[82] Kwon DS, Gregorio G, Bitton N, et al. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002;16:135–144.

[83] Lamb YN. Inclisiran: first approval. Drugs 2021;81:389–395.

[84] Larsen F, Madsen HO, Sim RB, et al. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004;279:21302–21311.

[85] Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010;20:169–177.

[86] Laubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009;114:4583–4591.

[87] Le Carré, J. Tinker, tailor, soldier, spy, 1st edn. (New York, Knopf; distributed by Random House) 1974.

[88] Lefort CT, Ley K. Neutrophil arrest by LFA-1 activation. Front Immunol 2012;3:157.

[89] Li C, Xue VW, Wang QM, et al. The Mincle/Syk/NF-kappaB signaling circuit is essential for maintaining the protumoral activities of tumor-associated macrophages. Cancer Immunol Res 2020;8:1004–1017.

[90] Lillegard JB, Sim RB, Thorkildson P, et al. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006;193:1589–1597.

[91] Linley A, Krysov S, Ponzoni M, et al. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood 2015;126:1902–1910.

[92] Liu P, Ridilla M, Patel P, et al. Beyond attachment: Roles of DC-SIGN in dengue virus infection. Traffic 2017;18:218–231.

[93] Madsen J, Gaiha GD, Palaniyar N, et al. Surfactant Protein D modulates HIV infection of both T-cells and dendritic cells. PLoS One 2013;8:e59047.

[94] Madsen HO, Satz ML, Hogh B, et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998;161:3169–3175.

[95] Malhotra R, Thiel S, Reid KB, et al. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990;172:955–959.

[96] Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1: 237–243.

[97] Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14:399–416.

[98] Mayilyan KR, Presanis JS, Arnold JN, et al. Heterogeneity of MBL-MASP complexes. Mol Immunol 2006;43:1286–1292.

[99] McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res 2015;107:331–339.

[100] Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol 2015;6:262.

[101] Mimura Y, Katoh T, Saldova R, et al. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell 2018;9:47–62.

[102] Mitchell DA, Fadden AJ, Drickamer K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 2001;276:28939–28945.

[103] Moller-Kristensen M, Thiel S, Sjoholm A, et al. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. Int Immunol 2007;19:141–149.

[104] Mondal N, Silva M, Castano AP, et al. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. J Biol Chem 2019;294:18465–18474.

[105] Mrksich M. An early taste of functional glycomics. Chem Biol 2004;11:739–740.

[106] Muliaditan T, Caron J, Okesola M, et al. Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis. Nat Commun 2018;9:2951.

[107] Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014;41:14–20.

[108] Murugaiah V, Varghese PM, Beirag N, et al. Complement proteins as soluble pattern recognition receptors for pathogenic viruses. Viruses 2021;13.

[109] Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014;136:16958–16961.

[110] Natoni A, Macauley MS, O’Dwyer ME. Targeting selectins and their ligands in cancer. Front Oncol 2016;6:93.

[111] Navarro-Sanchez E, Altmeyer R, Amara A, et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 2003;4:723–728.

[112] Neth O, Jack DL, Dodds AW, et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000;68:688–693.

[113] Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 2007;104:8433–8437.

[114] Nonaka M, Ma BY, Imaeda H, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem 2011;286:22403–22413.

[115] Nonaka M, Ma BY, Murai R, et al. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol 2008;180:3347–3356.

[116] Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001;194:781–795.

[117] Opzoomer JW, Anstee JE, Dean I, et al. Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Sci Adv 2021;7:eabg9518.

[118] Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985;316:452–457.

[119] Parekh R, Isenberg D, Rook G, et al. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 1989;2:101–114.

[120] Pinho SS, and Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015;15:540–555.

[121] Pohlmann S, Soilleux EJ, Baribaud F, et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A 2001;98:2670–2675.

[122] Presanis JS, Hajela K, Ambrus G, et al. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004;40:921–929.

[123] Presanis JS, Kojima M, Sim RB. Biochemistry and genetics of mannan-binding lectin (MBL). Biochem Soc Trans 2003;31:748–752.

[124] Radcliffe CM, Arnold JN, Suter DM, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 2007;282:7405–7415.

[125] Reid KBM. Complement component C1q: historical perspective of a functionally versatile, and structurally unusual, serum protein. Front Immunol 2018;9:764.

[126] Rook GA, Steele J, Brealey R, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 1991;4:779–794.

[127] Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167, 2861–2868.

[128] Royle L, Roos A, Harvey DJ, et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 2003;278:20140–20153.

[129] Saeland E, van Vliet SJ, Backstrom M, et al. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 2007;56:1225–1236.

[130] Saldova R, Royle L, Radcliffe CM, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007;17:1344–1356.

[131] Santos IK, Costa CH, Krieger H, et al. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect Immun 2001;69:5212–5215.

[132] Santulli G, Jankauskas SS, Gambardella J. Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk. Eur Heart J Cardiovasc Pharmacother 2021;7:e11–e12.

[133] Schwaeble WJ, Lynch NJ, Clark JE, et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2011;108:7523–7528.

[134] Schweitzer KM, Drager AM, van der Valk P, et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996;148:165–175.

[135] Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 2016;532:245–249.

[136] Sim RB, Schwaeble W, Fujita T. Complement research in the 18th-21st centuries: Progress comes with new technology. Immunobiology 2016;221:1037–1045.

[137] Simmons G, Reeves JD, Grogan CC, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003;305:115–123.

[138] Soilleux EJ, Barten R, Trowsdale J. DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J Immunol 2000;165:2937–2942.

[139] Soilleux EJ, Morris LS, Lee B, et al. Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV. J Pathol 2001;195:586–592.

[140] Soilleux EJ, Morris LS, Leslie G, et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol 2002;71: 445–457.

[141] Stover CM, Thiel S, Thelen M, et al. Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. J Immunol 1999;162:3481–3490.

[142] Strong P, Townsend P, Mackay R, et al. A recombinant fragment of human SP-D reduces allergic responses in mice sensitized to house dust mite allergens. Clin Exp Immunol 2003;134: 181–187.

[143] Stuart LM, Takahashi K, Shi L, et al. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol 2005;174:3220–3226.

[144] Summerfield JA, Sumiya M, Levin M, et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229–1232.

[145] Terada M, Khoo KH, Inoue R, et al. Characterization of oligosaccharide ligands expressed on SW1116 cells recognized by mannan-binding protein. A highly fucosylated polylactosamine type N-glycan. J Biol Chem 2005;280:10897–10913.

[146] Thiel S, Vorup-Jensen T, Stover CM, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997;386:506–510.

[147] Tomaiuolo R, Ruocco A, Salapete C, et al. Activity of mannose-binding lectin in centenarians. Aging Cell 2012;11:394–400.

[148] Tsakanova G, Stepanyan A, Nahapetyan K, et al. Serine proteases of the complement lectin pathway and their genetic variations in ischaemic stroke. J Clin Pathol 2018;71:141–147.

[149] Tsutsumi A, Takahashi R, Sumida T. Mannose binding lectin: genetics and autoimmune disease. Autoimmun Rev 2005;4:364–372.

[150] Valle-Argos B, Chiodin G, Bryant DJ, et al. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. Sci Rep 2021;11:11676.

[151] van Vliet SJ, Gringhuis SI, Geijtenbeek TB, et al. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol 2006;7:1200–1208.

[152] Wawrzinek R, Wamhoff EC, Lefebre J, et al. A remote secondary binding pocket promotes heteromultivalent targeting of DC-SIGN. J Am Chem Soc 2021;143:18977–18988.

[153] Weis WI, Drickamer K, and Hendrickson WA. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 1992;360:127–134.

[154] Wong D, Dorovini-Zis K. Regualtion by cytokines and lipopolysaccharide of E-selectin expression by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 1996;55:225–235.

[155] Yang SW, Cho EH, Choi SY, et al. DC-SIGN expression in Hofbauer cells may play an important role in immune tolerance in fetal chorionic villi during the development of preeclampsia. J Reprod Immunol 2017;124:30–37.

[156] Yang ZS, Huang SW, Wang WH, et al. Identification of Important N-Linked Glycosylation Sites in the Hemagglutinin Protein and Their Functional Impact on DC-SIGN Mediated Avian Influenza H5N1 Infection. Int J Mol Sci 2021;22:743–765.

[157] Yaseen S, Demopulos G, Dudler T, et al. Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2. FASEB J 2017;31:2210–2219.

[158] Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel) 2020;9:34–54.

[159] Zhao N, Wu J, Xiong S, et al. Mannan-binding lectin, a serum collectin, suppresses T-cell proliferation via direct interaction with cell surface calreticulin and inhibition of proximal T-cell receptor signaling. FASEB J 2017;31:2405–2417.

RIGHTS & PERMISSIONS

©The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.